IntRoductIon
The maintenance of homeostasis is a basic prerequisite for life, ensuring the stability of our body in response to external or internal stimuli (stressful stimuli). The maintenance of homeostasis requires alterations in the function of the endocrine system, as well as several other adaptive responses, involving changes in the behavior and the function of the central nervous system (CNS), immune, cardiovascular and other systems. A distorted regulation of the adaptive responses to various stressful stimuli may affect our physiologic functions, thus rendering us vulnerable to various disorders, such as depression and anxiety.
Corticotropin releasing hormone (CRH), or corticotropin releasing factor (CRF), a hypothalamic hormone, plays a key role in the maintenance of homeostasis. 1 CRF is secreted by the paraventricular nucleus of the hypothalamus in response to stress and is transported via the portal vein to the anterior lobe of the pituitary gland where it causes the release of corticotropin (ACTH). Subsequently, the ACTH is transported by the blood to the adrenals, where it stimulates the release of glucocorticoids ( Figure 1 ). 1, 2 In addition to the regulation of the hypothalamic-pituitary-adrenal axis (HPA), CRF plays an important role in stress as well as in many physiological and pathophysiological processes by being involved in the control of the CNS [3] [4] [5] [6] [7] [8] [9] as well as the cardiovascular, gastrointestinal, behavioral, immune and reproductive systems. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] peptIde and non-peptIde cRf analogs The CRF family CRF, which was first isolated from ovine hypothalamus (oCRF), belongs to a family of structurally related, highly homologous peptides (CRF-peptides) from several species, such as rat (h/rCRF), human (h/ rCRF), goat, cow, pig and xenopus CRF. 1, [27] [28] [29] [30] [31] [32] [33] In addition to CRF-peptides, the CRF family includes peptides from different species such as sauvagine, urotensin and urocortins, which are closely related to CRF (CRF-like peptides). Sauvagine (SVG) and urotensin (URO) have been characterized from the frog Phyllomedusa sauvagei and the sucker fish Catostomus commersoni, respectively, whereas urocortin (Ucn), urocortin II (UcnII) and urocortin III (UcnII) have been charac-terized in mammals. [34] [35] [36] [37] In addition to natural ligands, numerous peptide and non-peptide CRF analogs have been synthesized and are described below.
Structure and function of CRF family peptides
CRF, SVG and URO are peptides containing an amino-terminal (1-7 residues) and a carboxyl-terminal (36-41 residues) region connected to each other via an internal segment (8-32) of 25 amino acids. 38 This internal segment has a high chance of adopting an alpha-helical structure, which is the preferred conformation of CRF and its related peptides in hydrophobic or amphiphilic environments, whereas it is destabilized in aqueous environments. 38 , 39 The ability of CRF family peptides to adopt an alphahelical conformation in hydrophobic or amphiphilic environments led to the hypothesis that their binding to specific CRF receptors located in the amphiphilic environment of the cell membrane alters the conformation of peptides to a biologically active alpha-helical form. [38] [39] [40] Indeed, replacement of several residues of oCRF with alpha-helical preferred ones resulted in an increase of the biological potency of the peptide. 41 Similarly, Beyermann et al (2000) have suggested that the alpha helicity of an internal region connecting the amino-terminal (1-21 residues) and carboxyl-terminal (33-40 residues) regions of CRF and UCN is critical for peptide function. 42 Peptide analogs with internal regions constructed with highly flexible linkers such as those composed by ε-aminocaproic acid residues had lower potencies than UCN and CRF. 42 In contrast, analogs with linkers rich in alanines (alpha helical promoting amino acids) were equipotent to CRF. 42, 43 Similarly, connection of the amino-terminal and the carboxyl-terminal regions of UCN with a linker consisting exclusively of the negatively charged Glu and the positively charged Lys, which were arranged in such way that helix stabilization could occur by salt bridge formation between side chains at positions i and i4, resulted in an analog equipotent to UCN.
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Like the alpha-helical structure, the amino-terminal (first 21 residues) and carboxyl-terminal (last 8 residues) regions of CRF family peptides also play an important role in biological activity. Peptides having only one of these regions were biologically unimportant.
42,44 Furthermore, alanine substitution for several residues in the carboxyl-terminal region of CRF, removal of the last two amino acids of this region or replacement of the amidated carboxylterminal end of CRF with a free acid resulted in a significant to a complete loss of peptide biopotency. 1, 45 Similar to the carboxyl-terminal region, modifications of the amino-terminal region of CRF family peptides seriously affected their biological activities. In particular, removal of the first 8 amino-terminal residues of oCRF resulted in the biologically inactive analog, oCRF (9-41), whereas alanine substitution for almost all of the amino acids in this region resulted in a significant to a complete loss of CRF potency to stimulate ACTH release. 41, 45 Removal of the first 8 amino-terminal residues from oCRF, thus creating the oCRF (9-41), abolished its ability to stimulate ACTH release, without largely affecting the binding capacity of peptide, as measured by its ability to antagonize the effects of CRF. 41 Additional modifications of oCRF (9-41) by replacing some of its residues with alpha helical preferred ones created the first CRF antagonist, alpha-helical-CRF . 41 Similarly, removal of the first 11 aminoterminal residues from r/hCRF, and modifications of the truncated peptide (r/hCRF (12- 
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The binding of CRF family peptides to their receptors results in the activation of several heterotrimeric (αβγ) G-proteins having different Gα subunits, such as Gαs, Gαi, Gαo, Gαq, and Gαz. 50 Activation of Gα subunits by CRF receptors results in their dissociation from the Gβγ heterodimers and the subsequent regulation of several signaling pathways by the activated Gα subunits and the Gβγ dimers as well. Thus, the CRF1 receptor has been shown to activate through Gαs the adenylate cyclase, thus resulting in the accumulation of intracellular cAMP and the subsequent activation of protein kinase A (PKA) in various cell lines and tissues. [58] [59] [60] [61] [62] [63] In CHO cells expressing the CRF1 receptor, stimulation of the Gαs-cAMP-PKA pathway has been shown to stimulate the MAPK kinase, MEK1, which in turn activates the extracellular signal regulated kinase 1/2 (ERK1/2). 63 In the locus coeruleus, however, the CRF1-mediated stimulation of cAMP has been shown to activate ERK in a PKA-independent manner. 64 In addition to cAMP-dependent pathways, the activated CRF1 is able to inhibit the proliferation of corticotropic tumour (AtT-20) cells via a cAMP independent pathway. 65 Furthermore, following peptide binding, CRF1 and the CRF2 could alter the intracellular Ca 2+ signaling through Gαq-mediated or Gβγ-mediated stimulation of phospholipace C (PLC). 63, 66 Moreover, the CRF receptor-mediated activation of Gβγ-subunits has been shown to stimulate the phosphatidylinositol 3-kinase, which, through the production of PI (3, 4, 5) P3, activates the PLC, thus resulting in the mobilization of Ca 2+ . 63 The CRF1-mediated activation of PI3-K and PLC pathways, as well as mobilization of intracellular calcium stores, has been shown to activate ERK1/2. 63, 67, 68 had negligible intrinsic activity and it was 100 times more potent than the alpha-helical CRF (9-41). 46 More recently, new CRF antagonists and agonists have been developed, which are described below.
Non-peptide CRF antagonists
Several non-peptide CRF antagonists were developed as new leads in drug discovery to treat various stress-related disorders like depression, anxiety and addictive disorders.
1 Most non-peptide CRF antagonists are substituted five-membered rings or bicyclic and tricyclic rings and are discussed in detail below.
cRf ReceptoRs
CRF and its analogs exert their actions by interacting with two types of plasma membrane receptors, type 1 (CRF1) and type 2 (CRF2), which belong to the secretin-like family B of G protein-coupled receptors (GPCRs). 47, 48 In addition to CRF1 and CRF2, a third type of CRF receptor (CRF3) has been characterized from the catfish and it is expressed in the pituitary gland, urophysis and brain. 49 Furthermore, CRF1 and CRF2 receptors have been shown to be expressed as several functional splice variants (CRF1α-CRF1m, CRF2α, CRF2β and CRF2γ) and were extensively reviewed by Hillhouse and Grammatopoulos. 50 Among the splice variants of CRF1 receptor, CRF1α (which will be mentioned in this manuscript as CRF1 for simplicity) is the main functional variant that mediates the actions of CRF family peptides, whereas the other CRF1 variants have impaired functional properties. 50 In contrast to CRF1, the splice variants of CRF2 did not significantly differ pharmacologically from each other. 51, 52 The CRF1 and CRF2 receptors bind the CRF family peptides with different affinities. In particular, h/rCRF and oCRF bind to CRF1 with higher affinities than to CRF2, with oCRF being the most CRF1-selective peptide among the natural peptides of the CRF family. The affinity of oCRF for CRF1 receptor is 180-fold higher than that for CRF2. Similarly, the CRF non-peptide analogs (chemically described below) bind selectively to CRF1 receptor and antagonize the actions of CRF. In marked contrast, UcnII and UcnIII are the CRF2-selective natural peptides of the CRF family. On the other hand, UCN and SVG bind to CRF1 and CRF2 receptors with similar affinities. Similarly, the differ-In addition to ERK1/2, CRF1 and CRF2 are able to activate another functionally important kinase, the p38 mitogen protein kinase (p38 MAPK). 67, 69, 70 Even more interestingly, previous experiments have demonstrated that activation of CRF1 receptor by CRF in several brain regions resulted in the activation of ERK1/2 in only a few of them which are related to external environmental information processing and behavioral aspects of stress, thus suggesting a specific involvement of this pathway in mediating behavioral adaptation to stress. 71 In addition to the brain, the regulation of ERK1/2 activity by CRF receptors has also been identified in other tissues, such as the myometrium. (Figure 2) . 47, [73] [74] [75] [76] Experimental findings from numerous studies suggest that the Cdomain and the ILs of CRF receptors interact with various G-proteins, thus playing an important role in receptor-mediated signaling. 47, 60, [77] [78] [79] [80] [81] [82] In contrast to ILs which interact with the G-proteins, the ELs and the N-domain of the CRF receptors may, it has been suggested, interact with the CRF family peptides. Substitution of the N-domain of CRF1 with the corresponding one of GH-releasing hormone receptor abolished the binding of the radiolabelled astressin and UCN. 83 In contrast, the reverse chimeric receptor retained UCN and astressin binding, albeit with a reduced affinity, thus implying the participation of this region in peptide binding. 83 Similarly, a soluble form of the N-domain of CRF1 as well as a chimera created by replacing the extracellular region of activin receptor (a single membrane-spanning segment receptor) with the N-domain of CRF1 have been shown to bind to UCN and astressin with affinities that are lower than wild type receptor but still biologically considerable. [84] [85] [86] Structure-function studies have established that the amino acids, important for ligand binding, in the N-domain of CRF1 are located between residues 43-50 and 76-84 of the receptor. 87, 88 The precise interactions of the N-domain of CRF receptors with various peptides have been determined by crystallography and NMR studies using soluble forms of this receptor's segment. In particular, the crystal structure of the N-domain of the CRF1 receptor complex with CRF revealed that the peptide adopts a relatively straight, continuous alpha-helix and docks into a hydrophobic surface composed of the β1-β2 hairpin loop, loop 2, Tyr99, Pro69 and Cys68-Cys102 disulfide of the receptor's N-domain. 89 This crystallographic study has also proposed that the CRF binds with its amino-terminal residues 1-25 pointing toward the ELs and TMs of the receptor, whereas the carboxyl-terminal amino acids such as Leu37, Met38 and the C-terminal amide group (of residue 41) interact with the N-domain of CRF1. 89 Interestingly, NMR studies have revealed the important part played by the corresponding residues of astressin in peptide binding to a soluble form of CRF2β, despite the fact that the mode of binding of figure 2. Schematic illustration of CrF1 receptor. Hydropathy analysis of the cloned CrF receptors revealed the presence of seven hydrophobic regions (TM1-TM7) characteristic of the membrane-spanning segments of G-protein coupled receptors (GPCrs), which are depicted as cylinders and are connected to each other with three extracellular (els) and three intracellular loops (ils). 47 These loops as well as the amino-terminal extracellular domain (N-domain) and the carboxy-terminal intracellular tail (C-domain) are depicted as lines.
astressin has been proposed as being different than that of CRF. 89, 90 In contrast to several peptide residues that play a common role in the binding of different ligands, other peptide residues might be responsible for CRF1 or CRF2 selectivity. In particular, a crystallographic study on the N-domain of CRF1 proposed that the selective binding of CRF to CRF1 over UcnII and UcnIII may be due to interactions that place Arg35 of CRF between Glu39 of peptide and Glu104 of receptor. 89 The Arg35 of CRF is replaced with an Ala in UcnII and UcnIII, which is more compatible than Arg35 with the hydrophobic Pro of CRF2 that corresponds to Glu104 of CRF1, thus explaining the CRF2-selectivity of UcnII and UcnIII. 89 The N-domain of CRF1 receptor also contains three disulfide bridges between Cys30 and Cys54, Cys44 and Cys87 and Cys68 and Cys102, which play a crucial role in maintaining the receptor in its functional conformation. 86, 89, 91 Reduction of these bonds with DTT or mutation of Cys which participate in these bonds to Ser or Ala significantly decreased CRF binding. 92 The disulfide arrangement in the N-domain of CRF2β is identical to that of the corresponding region of CRF1, but different than that in the N-domain of CRF2α, which has four Cys linked to each other with disulfide bonds and one free Cys. 85, 86, 89, 93 In addition to the N-domain of CRF receptors, their extracellular loops as well as the extracellular portions of their TMs have been revealed as important for peptide binding. In particular, upon sauvagine binding to CRF1, residues 17 and 16 were shown to be located in close proximity to residue 117 in the extracellular portion of the TM1 and residue 257 in the second extracellular loop (EL2) of the receptor, respectively. 94, 95 The latter finding is in agreement with the results of an alanine mutagenesis study, which has suggested that Trp259 and Phe260 in the EL2 of CRF1 receptor most likely interact with ligands, and specifically with the amino-terminal residues 8-10 of SVG and the corresponding ones of CRF. 96 Furthermore, this study has proposed that the interaction between the amino-terminal region of CRF family peptides and Trp259 and Phe260 of CRF1 seems to be critical for receptor activation and the subsequent appearance of a biological effect. 96 In addition to EL2, the first extracellular loop (EL1) of CRF1 has been demonstrated as playing a part in peptide binding, given that the amino-terminally located residues 17 and 22 of UCN analogs have been shown in a recent study to be located in close proximity to residues Trp170-Glu179 in the EL1 of CRF1. 97 These results are in agreement with the experimental findings of a previous structure-function study, which suggested that residues 174-178 of EL1 are implicated in peptide binding. 98, 99 In addition to the binding sites, EL1 and EL2 contain two Cys, which are highly conserved among GPCRs and connect these regions of receptor with a disulfide bond that plays a very important role in receptor function. 92 Like EL1 and EL2, EL3 of CRF receptors also plays a role in peptide binding since it was demonstrated that Ala substitution for Tyr346, Phe347 and Asn348 in the EL3 of CRF1 significantly reduced the binding affinity of CRF. 100 The binding of CRF family peptides to CRF receptors has been proposed as being represented by a two-domain model, in which an initial interaction of the carboxyl-terminal region of peptides with the N-domain of receptor serves to dock the aminoterminal residues of peptides into a receptor's domain (J-domain) formed by the extracellular loops and the upper portions of TMs.
101,102 the membRane-spannIng segments
In contrast to the extracellular regions of CRF receptors which are important for the binding of the bulky peptides, the receptor TMs have been proposed as playing a role in the binding of small non-peptide CRF antagonists. Specifically, His199 and Met276 in the third (TM3) and the fifth (TM5) membranespanning segments of CRF1 have been suggested as being involved in the binding of the non-peptide antagonist, NBI 27914 (structure shown under compound 16c), because mutation of these residues to the corresponding ones of CRF2 significantly reduced NBI 27914 affinity for CRF1. 98, 103 Despite the fact that Met276 has been demonstrated as playing an indirect role in ligand binding, experimental findings from a structure-function study suggested that this residue is still very important for the interaction of CRF1 with non-peptide antagonists, most likely by positioning their heterocyclic core in the vicinity of Met276. 103 The involvement of CRF receptor TMs in ligand binding is further supported by the fact that the corresponding regions of family A GPCRs bind the non-peptide small molecules, such as catecholamines or acetylcholine. [104] [105] [106] [107] Although the TMs of CRF1 have been proposed as playing a role in the binding of small non-peptide CRF analogs, the exact interactions have not yet been determined due to the lack of significant structural information about these regions of CRF receptors and all family B GPCRs as well, in contrast to the TMs of family A GPCRs, which have been structurally characterized in many crystallographic, biophysical and biochemical studies. In addition, the development of accurate molecular models of family B GPCRs, which would provide structural information concerning their TMs, is very difficult because these receptors display very little sequence similarity to those of family A receptors. [108] [109] [110] Only recently, a study using the substituted cysteine accessibility method (SCAM) provided structural information about the TMs of CRF1 and suggested that, similarly to family A GPCRs, the TMs of this receptor form a water-accessible crevice, the binding-site crevice, which extends from the extracellular surface of CRF1 into the plane of the membrane and that the contact sites of small non-peptide CRF analogs must be located on the surface of this crevice. 111 Specifically, this study has shown that the endogenous Cys211 (in TM3), Cys233 (in TM4) and Cys364 (in TM7) are located on the surface of the binding-site crevice of CRF1. 111 Subsequently, Gkountelias et al. mapped the TM residues that form the surface of the binding-site crevice of CRF1 receptor by applying SCAM and starting from the extracellular portion of TM3. 112 The results of this study have suggested that Thr192, Ala193, Tyr195 and Asn196 of TM3 are located on the water-accessible surface of the binding-site crevice of CRF1 and that the pattern of accessibility is consistent with an alpha-helical conformation for this region of TM3. 
non-peptIde cRf1-selectIve antagonIsts
Several non-peptide CRF antagonists were developed as new leads in drug discovery to treat various stress-related disorders like depression, anxiety and addictive disorders. Most non-peptide CRF antagonists discovered to date are substituted five-membered rings or bicyclic and tricyclic rings and bind selectively to CRF1. The non-peptide CRF antagonists offer advantages over the peptide congeners in terms of stability, ease of preparation, ease of further modification to enhance the pharmacokinetic profile and better brain penetrability.
Substituted Pyrazolones:
Nova Pharmaceuticals reported the synthesis of 4-substituted thiopyrazolones and its disulfide congener. 113 These derivatives inhibited the binding of [ 
Thiazolo[4,5-d]-pyrimidines:
A research study performed by DuPont Pharmaceuticals reported various thiazolo [4,5-d] pyrimidines having the general structure 4. 114 Substitution of noncyclic diamino groups in R1 position was found to increase the binding affinity of CRF for the human CRF1 receptor compared to the cyclic amino group (e.g. morpholine). The thiazolones (X = O) were also equipotent in binding to CRF1 receptors compared to the precursor thiazolothiones (X = S). 
Quinolines and Isoquinolines:
In search of novel CRF1 antagonists with water solubility, Chen et al. prepared compound 5 with high pKa (pKa = 7.1). 115 However, clinical trials of this compound have been discontinued due to its hepatotoxicity. Furthermore, 4-substituted 8-aryl-2-methylquinolines with general structure 6 have recently been synthesized. Since the pKa of the 4-amino quinolone was about 9.08, it has been speculated that these compounds should be largely charged at physiological pH (7.4) thus increasing water solubility. Presence of the dipropylamino and N-cyclopropane-methyl-N-propylamino group greatly enhanced activity compared to the smaller diethylamino group. Indeed, non-polar groups of the aromatic ring enhance activity. I-Sauvagine as a radioligand. 116 Compounds with mono-substituted aryl groups were found to have lower affinity than those with di-substitution at both the ortho and para positions with at least one methoxy group at one ortho position. Compounds having a dipropylamino group at 4-position (-N-Pr2) showed enhanced affinity, as seen in compound 7. 
Pyrimidine derivatives:
High lipophilicity, poor water solubility and long half-life of many potent CRF1 receptor antagonists make them unattractive for clinical development and hinder further development. Yoon et al. developed less lipophilic and more water soluble aryl pyrimidine derivatives in order to improve their pharmacokinetic profile. 117 Further introduction of a small alkoxy group at the available un-substituted positions in the pyrimidine ring enhanced the affinity. Further modifications of the pyrimidine 2-aryl group yielded 2-(2,4,6-tri-substituted) compounds, the most potent of which was the 2,4-dimethoxy-6-chloro derivative 8. Screening of a library of compound by DuPont Pharmaceuticals revealed that compound 9 inhibited [
125 I] Tyr-oCRH binding in rat frontal cortex homogenates. 118 Initial structure-activity relationship studies (SAR) of this lead compound resulted in the synthesis of compound 10, which was subjected to further optimization. Replacement of the bromo group with methyl, trifluoromethyl or thiomethyl resulted in compounds having comparable affinities to 10, while removal of any substituent at that position greatly reduced receptor binding affinity. Substitution of the 4-position isopropyl group with larger groups (e.g. butyl, t-butyl) resulted in further decreased receptor binding than groups which have approximately the same size or smaller than isopropyl (e.g. methoxy) as in compound 11.
In addition, it was noticed that substitution of the 4-or 6-positions of the pyrimidine ring with groups larger than methyl decreased receptor binding activity. Retaining the methyl at 6-position while having different selected substituents at 4-position (R1) of the pyridine ring yielded many compounds 12a, 12b, 12c and 12d with enhanced activity. Removal of the 1-or 5-nitrogen in the triazene compound 13 119 resulted in active pyrimdines 14 and 15 according to Chen et al. 120 However, removal of the 3-nitrogen of the triazine resulted in complete loss of activity. A pharmacophore model has been proposed where the aniline group was predicted to be orthogonal to and below the pyrimidine ring. Addition of small groups (e.g. methyl, ethyl, chloro and bromo) resulted in compounds 16a, 16b, 16c (NBI 27914) and 16d with nanomolar range receptor binding affinity. 
Pyridine derivatives:
Several promising pyridines were developed at Pfizer. Compound 17 showed increased binding affinity but poor pharmacokinetic profile. To improve the pharmacokinetic properties, the oxygen atom in the alkoxy or aryloxy groups have been replaced by a nitrogen atom to increase basicity and thus water solubility. 121 Thus replacing the alkoxy group with alkylamino function resulted in compound 18a, which had higher basicity and increased aqueous solubility in simulated gastrointestinal fluid. Further structural optimization has been achieved by replacing the methyl group at the para-position of the 2-phenoxy ring with chloro or bromo atoms, thus yielding the compounds 18b and 18c. Further structural modifications resulted in compound 19a and 19b with increased polarity and decreased binding. 
SAR studies of this class demonstrated that replacement of the phenyl group (21a, Ki = 511 nM) with 2-Cl phenyl resulted in enhanced binding affinity (21b, Ki = 15 nM). Similarly, substitution with 2,4-dichlorophenyl created the most potent derivative of the series (21c with Ki = 5 nM). However, unlike most similar non-peptide CRF antagonists, the 2,4,6-trimethylphenyl derivative displayed 17-fold reduction of binding affinity (21d, Ki= 93 nM).
As expected, SAR studies also revealed that the presence of non-cyclic dialkyl amino groups with small groups had better activity than their cyclic counterparts (e.g. compounds 22a and 22b).
Compound 23 showed excellent potential in depression and anxiety tests; however, it caused reversible increase in hepatic enzymes, which hindered its further development. Attempts to lower the lipophilicity by substitution of N-alkyl side chain with heterocycles, while retaining the CRF antagonistic activity, were sought. 125 Several 1,2,4-oxadiazolyl derivatives were prepared, among them compound 24a (pKi=7.2±0.1) and 24b (pKi=7.6±0.1), which exhibited an improved metabolic stability. The best combination of metabolic stability and CRF binding affinity was observed in compound 24c (pKi=8.1±0.1). 
Purines:
Many substituted purin-8-analogs have emerged as a new class of CRF antagonists. 126 Based on the previous SAR work, the 2-bromo-4-isopropylphenyl derivatives were selected as lead compounds. Compound 25a had weak CRF binding affinity (Ki=890 nM), in contrast to its N-methyl derivative 25b, which had a high binding affinity (Ki= 5 nM). Further modification with steric bulky groups resulted in decreased binding. The dialkylamine substituted derivatives had higher affinities than mono-substituted compounds (compounds 26a, 26b, 26c and 26d) . The replacement of the oxo group with a chloro function created a derivative with excellent binding affinity (27a, Ki=1.5 nM). Similarly, the replacement with small alkoxy groups (e.g. methoxy) resulted in the high affinity derivative 27c (Ki=1.5 nM). In contrast, the binding affinity was dramatically reduced by the replacement of chloro function with morpholine (27b, Ki=345 nM). Larger-size groups resulted in loss of affinity.
non-peptIde cRf ReceptoR antagonIsts In clInIcal tRIals
Several non-peptide CRF receptor antagonists, including antalarmin, are currently being studied in clinical trials. Antalarmin blocks the CRF1 receptor and, consequently, reduces the release of ACTH in response to chronic stress. 127 Antalarmin reduces the behavioral response to stressful stimuli. 128 It should be mentioned that several newer non-peptide CRF antagonists are currently under development, 129 tar-geting specific brain regions with the aim of ameliorating the health consequences of chronic stress and for use in the clinical management of anxiety and depression. [130] [131] [132] 
Promising results have also been observed using antalarmin as a potential treatment for CRF-induced hypertension. Central administration of CRF results in endocrinological, cardiovascular and behavioral effects that suggest stress or anxiety. Among these is a marked pressor response. Antalarmin was found to antagonize the pressor effect induced by central CRF. 133 Similar promising results for antalarmin and other CRF1 antagonists were also observed in the area of drug addiction disorders. Evaluation of antalarmin effects on cocaine dependence in cocaine-addicted monkeys showed a reduction of its use. Similarly, antalarmin tested on cocaine-addicted rats prevented dose escalation, suggesting that it might modulate the cocaine addictive effects over time. Antalarmin also displayed positive effects in reducing withdrawal symptoms from chronic opioid use and significantly reduced self-administration of ethanol in ethanoladdicted rodents. [134] [135] [136] [137] Antalarmin also showed anti-inflammatory effects and has been suggested as having potential uses in the treatment of inflammatory conditions such as arthritis 138 as well as stress-induced gastrointestinal ulcers 139 and irritable bowel syndrome. 140, 141 Chronic blockade of CRF1 with systemic antalarmin significantly ameliorated rat adjuvant-induced arthritis, reducing the severity of inflammation in peripheral joints, this evidenced by clinical and histopathology results, and weight loss associated with disease onset. Antalarmin neither induced nor exacerbated arthritis expression in rats, despite suppression of levels of adjuvant-induced corticosterone, the major antiinflammatory glucocorticoid in rats. Systemic blockade of CRF1 appeared to predominantly block peripheral pro-inflammatory effects of immune CRF rather than the systemic glucocorticoid mediated antiinflammatory effects of hypothalamic CRF. Results indicate that chronic treatment with a CRF1 antagonist attenuates progressive inflammation-induced degeneration of synovia, cartilage and bone in arthritic joints, suggesting that antalarmin may have therapeutic potential in treatment of human autoimmune and inflammatory disorders. 138 Upon exposure to prolonged stress, rats develop gastric ulceration, enhanced colon motility with depletion of its mucin content and signs of physiological and behavioral arousal. When antidepressants (fluoxetine and bupropion), anxiolytics (diazepam and buspirone) or antalarmin were evaluated for their potential to modify these responses, fluoxetine, bupropion, diazepam and antalarmin all suppressed stress-induced gastric ulceration in male SpragueDawley rats exposed to four hours of plain immobilization. Antalarmin was found to produce the most pronounced anti-ulcer effect and additionally suppressed the stress-induced colonic hypermotility, mucin depletion, autonomic hyperarousal and struggling behavior. Non-peptide CRF1 antagonists may therefore be of value as prophylactics against stress ulcer in the critically ill and as therapeutics for other related gastrointestinal disorders such as peptic ulcer disease and irritable bowel syndrome. 139 The characterization of neuroendocrine-regulating CRF family peptides, in conjunction with the cloning and pharmacological characterization of the two major CRF receptor subtypes (CRF1 and CRF2) and the development of selective CRF receptor antagonists, provided new insights to explain the mechanisms of stress and the potential involvement of the CRF system in different pathophysiological conditions, including gastrointestinal disorders, mainly irritable bowel syndrome (IBS), and psychopathologies such as anxiety/depression. Compelling pre-clinical data demonstrated that central CRF administration mimics acute stress-induced colonic responses and enhances colorectal distension-induced visceral pain in rats through CRF1 receptors. Similarly, peripheral CRF reduced the pain threshold to colonic distension and increased colonic motility in both humans and rodents. These observations mimic the manifestations of IBS characterized by abdominal bloating and discomfort and altered bowel habits. CRF1 pathways have been implicated in the development of anxiety/depression and these psychopathologies, together with stressful life events, have high co-morbidity with IBS and are considered significant components of the disease. CRF1 receptors have been suggested as a target to treat IBS. Peripherally acting CRF1 antagonists might directly improve IBS symptoms, as related to motility, secretion and immune response. On the other hand, central actions will be beneficial for the prevention of the psychopathologies that co-exist with IBS and as a way to modulate the central processing of stress-and visceral pain-related signals. 140, 141 summaRy CRF plays a key role in the maintenance of homeostasis by regulating the hypothalamic-pituitaryadrenal axis, functioning as a neurotransmitter within the central nervous system and being involved in the control of the cardiovascular, gastrointestinal, behavioral, immune and reproductive systems. CRF exerts its actions by interacting with the CRF1 and CRF2 receptors, which belong to family B of G-protein coupled receptors. Considerable progress has been made in the determination of the structure and function of peptide and non-peptide CRF analogs, thus advancing to some extent the development of new compounds, including non-peptide CRF1-selective antagonists. The non-peptide CRF analogs have significantly contributed to the determination of the role of CRF and its receptors in several physiological and pathophysiological conditions. Progress in elucidating the interactions of CRF ligands with their receptors will further advance the design and synthesis of new CRF analogs with potential clinical applications. 
